| Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung s disease. | None |
| RET oncogene. | None |
| Developmental and denervation changes in c-ret proto-oncogene expression in chick motoneurons. | None |
| Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. | None |
| Somatic mutations of the RET proto-oncogene are not required for tumor development in multiple endocrine neoplasia type 2 (MEN 2) gene carriers. | None |
| The MEN II syndromes and the role of the ret proto-oncogene. | None |
| The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. | None |
| Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene. | None |
| RET proto-oncogene point mutations in sporadic neuroendocrine tumors. | None |
| Mouse ret finger protein (rfp) proto-oncogene is expressed at specific stages of mouse spermatogenesis. | None |
| The RET proto-oncogene: a challenge to our understanding of disease pathogenesis. | None |
| Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. | None |
| Germline mutation of the RET proto-oncogene in children with total intestinal aganglionosis. | None |
| A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. | None |
| A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. | None |
| Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. | None |
| RET proto-oncogene is important for the development of respiratory CO2 sensitivity. | None |
| Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene. | None |
| The role of the ret proto-oncogene in human disease. | None |
| Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. | None |